HighTide Therapeutics

Solutions for Life

Our Pipeline

Our Mission

HighTide Therapeutics Inc. is dedicated to the discovery and development of innovative therapeutics for people suffering from chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unsatisfied market needs.

Our Pipeline

HTD1801

New molecular entity: ionic salt of two active moieties

Learn More
HTD4010

Peptide analog of RegIII/PAP protein active fragment

Learn More
HTD2802

An innovative fixed dose combination of two known compounds with clear differentiation for unmet clinical needs

Learn More

Latest News

HighTide Therapeutics to Present at Biotech Showcase™ 2019 in San Francisco

[Rockville, Maryland, Dec. 11, 2018] — HighTide Therapeutics, today announced that it will present...

Read more
HighTide Therapeutics Receives Fast Track Designation from the U.S. FDA for HTD1801 Treating Nonalcoholic Steatohepatitis (NASH)

[Rockville, Maryland, Nov. 27, 2018] — HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced...

Read more
HighTide Therapeutics Presented at the 2nd Annual Pediatric Autoimmune Liver Disease Symposium and Family Day

[Rockville, Maryland, October 3, 2018] — HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company participated...

Read more
HighTide Therapeutics Receives Fast Track Designation from the U.S. FDA for HTD1801 Treating Primary Sclerosing Cholangitis

HighTide Therapeutics Inc., a globally focused clinical-stage biopharmaceutical company, announced that the U.S. FDA...

Read more
Read More